The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

We have in-house Spravato therapy for persisting depression and may refer you to explore TMS therapy, Stellate Ganglion Block, Ketamine Infusion and integration therapy at our Westmont flagship.

GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

Ketamine has long been seen as a potential ... who have cycled through multiple treatments without relief. Spravato (esketamine) has been touted as a potential blockbuster for Janssen, which ...

In 2019, the FDA approved a ketamine-related chemical developed by Johnson & Johnson for severe depression. The drug, Spravato, is subject to strict FDA safety rules on where and how it can be ...

Ketamine can trigger symptoms similar to those of schizophrenia, but it isn’t known to cause the disorder itself. Ketamine is gaining attention for its potential to treat depression and other ...

Esketamine, an anaesthetic derived from Ketamine, was approved for use in treating patients with Major Depressive Disorder (MDD) by the Health Sciences Authority (HSA) back in Oct. 2020.

Emerging evidence suggests that oral Ketamine therapy may have a specific role in managing treatment-resistant chronic pain. This study aimed to assess the effectiveness of oral ketamine within a ...

A researcher is working on apps that he hopes will be able to identify signs of depression. The programs take and analyze photos of the eyes and face while someone uses the smartphone for other ...